As expected, scRNA-seq feature plots revealed that transfection with sgTACC3 decreased the proportions of PDCD1+CD8+ T cells, TOX+CD8+ T cells, and HAVCR2+CD8+ T cells, which are considered exhausted CD8+ T cells that have lost their antitumor activity (Supplementary Fig. 4a).23 To evaluate the impact of tumorous TACC3 on CD8+ T cells, a CD8+ T-cell-mediated tumor killing assay using TACC3-knockdown and TACC3-overexpressing HCC cell lines was subsequently performed (Fig. 3a and Supplementary Fig. 4b‒i). This evidence concerns the gene TACC3 and neoplasm.